Drugmakers Metsera and Maze Raise Combined $415 Million in IPOs
A pair of drugmakers priced their initial public offerings on Thursday, delivering the best month for US health care first-time share sales since October.
Drug developer Maze Therapeutics eyes up to $728 million valuation in US IPO
By Arasu Kannagi Basil (Reuters) -Drug developer Maze Therapeutics said on Monday it was targeting a valuation of up to $728.1 million in its New York initial public offering, set to be the first U.S.
Metsera Seeks $289M Raise, $1.78B Valuation in IPO
The GLP-1 IPO arena has been heating up for the past two years and Metsera’s ask is one the largest in recent history.
Metsera, Maze secure combined $415 million in IPOs
The offerings reflect an increase in IPO activity that could continue, as four other biotechs recently outlined plans to go public.
Weight-loss drug developer Metsera targets up to $1.78 billion valuation in US IPO
Metsera, which is developing weight-loss drugs, said on Monday it is seeking a valuation of up to $1.78 billion in its U.S. IPO, aiming to capitalize on Wall Street's insatiable appetite for such treatments.
Obesity drug developer Metsera sets terms for $275M IPO
Metsera (MTSR), which is developing ultra-long-acting drugs for the treatment of obesity, has set terms for an upsized $275M initial public offering. In a recent SEC filing, Metsera (MTSR) said it was looking to offer 17.
ENDPOINTS NEWS3h
Fri­day IPO dou­ble­head­er from Maze and Met­sera brings life to biotech de­buts
Metsera and Maze Therapeutics priced their Nasdaq IPOs, raising $275M and $140M respectively. Both companies backed by ARCH ...
FierceBiotech3d
Metsera eyes $289M IPO to fund phase 3 weight loss trial
Metsera has set its sights on a hefty $289 million IPO as the next-gen obesity biotech seeks to fund a phase 3 trial of its ...
GlobalData on MSN2d
GLP-1RA developer Metsera targets $289m IPO
Metsera is aiming to put its weight loss drug MET-097i, which boasts of a longer half-life, through Phase III trials.
Metsera Readies $275 Million IPO For Obesity Treatments
Metsera, Inc. aims to raise $275 million in an IPO to fund its clinical-stage biopharma programs targeting obesity and ...
The Pharma Letter2d
Three biotechs go public as IPO momentum increases
The biotech IPO landscape gains momentum in 2025 as Aurion Biotech, Maze Therapeutics, and Metsera file for offerings. Aurion focuses on regenerative therapies, Maze advances precision medicines for ...
Google Ventures-Backed Biotech Metsera Seeks $292 Million in IPO
Metsera Inc. is seeking to raise $292 million in an initial public offering, joining a clutch of health-care firms set to ...